Most importantly, since NRP2 does not seem to play a key role in normal adult tissues, blocking the effects of SEMA3F on DCIS progression might be a good new therapeutic approach for preventing secondary effects on healthy regions [88]. Here, SEMA3F is linked to ductal breast carcinoma in situ.